Zeiss reveals Humphrey Field Analyzer II-i with Guided Progression Analysis software

Article

Carl Zeiss Meditec has unveiled the most advanced visual field testing platform available today - the Humphrey Field Analyzer II-i (HFA II-i) with Guided Progression Analysis (GPA) software.

Carl Zeiss Meditec has unveiled the most advanced visual field testing platform available today - the Humphrey Field Analyzer II-i (HFA II-i) with Guided Progression Analysis (GPA) software. The new system has been designed to accurately determine the stage of glaucoma and progression rate.

The GPA programme, which uses Visual Field Index, has been developed based on data from a 15 centre international clinical trial. It allows the platform to automatically summarize a patient's visual field test results, rate of visual field deterioration and therefore risk of future vision loss, which is then printed onto a single page in a simple format.

According to its manufacturers, HFA II-i with the new GPA software helps doctors to ensure that their glaucoma patients receive the best course of treatment and that vision loss is prevented or minimized.

Carl Zeiss Meditec also announced a host of new product and software upgrade launches at this year's ASCRS congress in Chicago, US. Their product portfolio now includes advanced algorithms for the Cirrus HD-OCT and Stratus OCT systems, new OCT software for their Visante OCT platform and an integrated workflow system for ophthalmic surgery (CALLISTO eye).

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.